Goto et al., in a 2019 study, showed that sPD-1 level was found to be significantly higher in ovarian cancer patients and also non-small cell lung cancer, renal cell carcinoma, multiple myeloma, and acute myeloid leukemia patients compared to healthy individuals [18]. This evidence concerns the gene HOXD13 and plasma cell myeloma.